Erin F. Cobain
0000-0001-9602-8611
Publication & Citation Trends
Publications
0 total
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Cited by 0
Semantic Scholar
Abstract PS5-04-19: 70-gene signature high risk classification provides stronger prognostic value than histologic grade in hr+ her2- early breast cancer
Cited by 0
Semantic Scholar
Abstract PS2-07-22: Serial, multi-omic, multi-analyte, liquid biopsy monitoring of metastatic lobular breast cancer to detect clinically-relevant heterogeneity and evolution
Cited by 0
Semantic Scholar
Abstract P4-09-22: Distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC)
Cited by 0
Semantic Scholar
Phase 1 dose-escalation trial of talazoparib in combination with belinostat in select advanced solid tumors.
Cited by 2
Semantic Scholar
Antibody drug conjugates treatment response score (ADC TRS) for sequencing trastuzuamb deruxtecan (T-DXd) and sacituzumab govitecan (SG) in advanced breast cancer (aBC).
Cited by 1
Semantic Scholar
Abstract P1-05-15: A real-world analysis of cancer prevention measures among individuals with hereditary breast and ovarian cancer (HBOC) syndromes and no personal history of malignancy
Cited by 0
Semantic Scholar
Association of MammaPrint and clinical outcomes by race among 5000 individuals with HR+HER2- early stage breast cancer enrolled in FLEX.
Cited by 1
Semantic Scholar
Research Topics
Advanced Breast Cancer Therapies
(28)
Breast Cancer Treatment Studies
(24)
HER2/EGFR in Cancer Research
(20)
Cancer Genomics and Diagnostics
(20)
Cancer Treatment and Pharmacology
(16)
Affiliations
Novartis (Switzerland)
Janssen (Belgium)
Eli Lilly (United States)
University of Pittsburgh
Pfizer (United Kingdom)